Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China

3 abstracts

Abstract
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).
Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China,
Abstract
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
Org: Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Musashino Red Cross Hospital, Chiba University, Graduate School of Medicine, The University of Tokyo,
Abstract
A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC).
Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China, Tianjin Cancer Hospital Airport Hospital, Liver Cancer Center, Tianjin Medical university cancer institute & Hospital, National Clinical Research Center for Cancer,